Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss

A growing appreciation of the overlapping neuroendocrine mechanisms controlling energy balance has highlighted combination therapies as a promising strategy to enhance sustained weight loss. Here, we investigated whether amylin- and glucagon-like-peptide-1 (GLP-1)-based combination therapies produce...

Descripción completa

Detalles Bibliográficos
Autores principales: Liberini, Claudia G., Koch-Laskowski, Kieran, Shaulson, Evan, McGrath, Lauren E., Lipsky, Rachele K., Lhamo, Rinzin, Ghidewon, Misgana, Ling, Tyler, Stein, Lauren M., Hayes, Matthew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560126/
https://www.ncbi.nlm.nih.gov/pubmed/31186439
http://dx.doi.org/10.1038/s41598-019-44591-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560126/
https://www.ncbi.nlm.nih.gov/pubmed/31186439
http://dx.doi.org/10.1038/s41598-019-44591-8

Ejemplares similares